Influences	O
on	O
the	O
pharmacokinetics	O
of	O
oxycodone	O
:	O
a	O
multicentre	O
cross	O
-	O
sectional	O
study	O
in	O
439	O
adult	O
cancer	B-Cancer
patients	O
.	O

OBJECTIVE	O
:	O

Oxycodone	O
is	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
cancer	B-Cancer
pain	O
,	O
but	O
little	O
is	O
known	O
of	O
its	O
pharmacokinetics	O
in	O
cancer	B-Cancer
pain	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
relationships	O
between	O
ordinary	O
patient	O
characteristics	O
and	O
serum	B-Organism_substance
concentrations	O
of	O
oxycodone	O
and	O
the	O
ratios	O
noroxycodone	O
or	O
oxymorphone	O
/	O
oxycodone	O
in	O
cancer	B-Cancer
patients	O
.	O

METHODS	O
:	O

Four	O
hundred	O
and	O
thirty	O
-	O
nine	O
patients	O
using	O
oral	B-Organism_subdivision
oxycodone	O
for	O
cancer	B-Cancer
pain	O
were	O
included	O
.	O

The	O
patients	O
'	O
characteristics	O
(	O
sex	O
,	O
age	O
,	O
body	B-Organism_subdivision
mass	O
index	O
[	O
BMI	O
]	O
,	O
Karnofsky	O
performance	O
status	O
,	O
"	O
time	O
since	O
starting	O
opioids	O
"	O
,	O
"	O
oxycodone	O
total	O
daily	O
dose	O
"	O
,	O
"	O
time	O
from	O
last	O
oxycodone	O
dose	O
"	O
,	O
use	O
of	O
CYP3A4	O
inducer	O
/	O
inhibitor	O
,	O
"	O
use	O
of	O
systemic	O
steroids	O
"	O
,	O
"	O
number	O
of	O
medications	O
taken	O
in	O
the	O
last	O
24	O
h	O
"	O
,	O
glomerular	B-Multi-tissue_structure
filtration	O
rate	O
(	O
GFR	O
)	O
and	O
albumin	O
serum	B-Organism_substance
concentrations	O
)	O
influence	O
on	O
oxycodone	O
serum	B-Organism_substance
concentrations	O
or	O
metabolite	O
/	O
oxycodone	O
ratios	O
were	O
explored	O
by	O
multiple	O
regression	O
analyses	O
.	O

RESULTS	O
:	O

Sex	O
,	O
CYP3A4	O
inducers	O
/	O
inhibitors	O
,	O
total	O
daily	O
dose	O
,	O
and	O
"	O
time	O
from	O
last	O
oxycodone	O
dose	O
"	O
predicted	O
oxycodone	O
concentrations	O
.	O

CYP3A4	O
inducers	O
,	O
total	O
daily	O
dose	O
,	O
and	O
"	O
number	O
of	O
medications	O
taken	O
in	O
the	O
last	O
24	O
h	O
"	O
predicted	O
the	O
oxymorphone	O
/	O
oxycodone	O
ratio	O
.	O

Total	O
daily	O
dose	O
,	O
"	O
time	O
from	O
last	O
dose	O
to	O
blood	B-Organism_substance
sample	I-Organism_substance
"	O
,	O
albumin	O
,	O
sex	O
,	O
CYP3A4	O
inducers	O
/	O
inhibitors	O
,	O
steroids	O
,	O
BMI	O
and	O
GFR	O
predicted	O
the	O
noroxycodone	O
/	O
oxycodone	O
ratio	O
.	O

CONCLUSION	O
:	O

Women	O
had	O
lower	O
oxycodone	O
serum	B-Organism_substance
concentrations	O
than	O
men	O
.	O

CYP3A4	O
inducers	O
/	O
inhibitors	O
should	O
be	O
used	O
with	O
caution	O
as	O
these	O
are	O
predicted	O
to	O
have	O
a	O
significant	O
impact	O
on	O
oxycodone	O
pharmacokinetics	O
.	O

Other	O
characteristics	O
explained	O
only	O
minor	O
parts	O
of	O
the	O
variability	O
of	O
the	O
outcomes	O
.	O

